AGAP14P: GPCR Family Protein and Potential Drug Target (G653259)

Target Name: AGAP14P

NCBI ID: G653259

AGAP14P

Other Name(s): bA145E20.1 | CTGLF11P | ArfGAP with GTPase domain, ankyrin repeat and PH domain 14, pseudogene | AGAP14

AGAP14P: GPCR Family Protein and Potential Drug Target

AGAP14P (BAA145E20.1) is a protein that is expressed in various tissues of the body, including the brain. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play a crucial role in cellular signaling. AGAP14P is one of the most well-studied GPCR family proteins, and several studies have identified potential drug targets and biomarkers associated with its function.

The AGAP14P gene was first identified in the late 1990s using DNA-based sequencing techniques. The gene encodes a protein that consists of 214 amino acid residues. The protein has a unique structure, with a long extracellular domain that is involved in its interactions with ligands , as well as a short intracellular domain that is involved in its signaling pathway.

One of the most significant features of AGAP14P is its role in cell signaling. GPCR family proteins are known for their ability to transmit signals from the cell surface to intracellular targets, such as the brain. AGAP14P is involved in several signaling pathways, including the regulation of neurotransmitter release, cell survival, and neuroplasticity.

One of the most well-studied functions of AGAP14P is its role in neurotransmission. Several studies have shown that AGAP14P is involved in the regulation of neurotransmitter release from neurons, which is critical for the function of the nervous system. For example, AGAP14P has been shown to play a role in the regulation of dopamine release from the brain, and changes in AGAP14P levels have been linked to changes in dopamine levels.

In addition to its role in neurotransmission, AGAP14P is also involved in several other cellular processes. For example, it has been shown to play a role in cell survival, and is involved in the regulation of cell apoptosis (programmed cell death). AGAP14P has has also been shown to be involved in the regulation of neuroplasticity, which is the ability of the brain to change and adapt in response to new experiences or learning.

Several studies have identified potential drug targets and biomarkers associated with AGAP14P. One of the most promising targets is the protein Shc/YAP, which is a known GPCR partner of AGAP14P. Studies have shown that the interaction between AGAP14P and Shc/YAP is involved in several cellular processes, including neurotransmission, cell survival, and neuroplasticity.

Another potential drug target associated with AGAP14P is the protein TrkB, which is also a GPCR partner of AGAP14P. Studies have shown that the interaction between AGAP14P and TrkB is involved in the regulation of neurotransmission, as well as the regulation of cell survival and neuroplasticity.

In addition to these potential drug targets, AGAP14P has also been identified as a potential biomarker for several diseases, including neurodegenerative disorders and psychiatric disorders. Several studies have shown that AGAP14P levels are altered in the brains of individuals with these disorders, and that these changes are associated with negative symptoms.

Overall, AGAP14P is a well-studied protein that is involved in several critical cellular processes in the brain. Its function as a GPCR partner and its potential as a drug target and biomarker make it an attractive target for further research. Further studies are needed to fully understand the role of AGAP14P in cell signaling and its potential as a therapeutic intervention.

Protein Name: ArfGAP With GTPase Domain, Ankyrin Repeat And PH Domain 14, Pseudogene

The "AGAP14P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AGAP14P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets